Home Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease
 

Keywords :   


Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease

2014-11-05 05:46:07| drugdiscoveryonline Home Page

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease

Tags: with study eye phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
15.11171
15.11 3FLYOVER
15.11 PSA8 - 1ed
15.11DMC RAVEN 18g
15.11LOVE or DEAD Blu-ray
15.11 HSGI SURE-GRIP PADDED BELT a-tacs au
15.11 BOUNTY HUNTER
15.11
More »